AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own EPAM Systems, you need to believe it can shift from traditional project work toward higher value AI and platform-led services while stabilizing margins. The OpenAI Advanced Partner status supports this transition by deepening AI credentials, but it does not remove near term pressures from wage inflation, pricing competition and slower discretionary tech spending, which still look like the key catalysts and risks around earnings over the next few quarters.
Among recent announcements, the multi-year Anthropic partnership in May 2026 looks especially relevant here, because it shows EPAM building a multi-model, multi-partner AI offering rather than relying on a single provider. Combined with the OpenAI collaboration, this broadens EPAM’s role in large enterprise AI deployments, but also raises the execution risk of monetizing significant AI investments at a time when net margins remain below prior levels.
Yet beneath the excitement around EPAM’s OpenAI partnership, investors should still be aware of the risk that...
Read the full narrative on EPAM Systems (it's free!)
EPAM Systems' narrative projects $6.5 billion revenue and $542.9 million earnings by 2029.
Uncover how EPAM Systems' forecasts yield a $144.06 fair value, a 36% upside to its current price.
The most pessimistic analysts were already assuming only about 5.1 percent annual revenue growth and US$532.8 million in earnings by 2029, so this OpenAI news could either soften their concerns about pricing pressure and integration risks or reinforce them, depending on how you think AI investments will actually affect EPAM’s profitability.
Explore 7 other fair value estimates on EPAM Systems - why the stock might be worth just $107.00!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com